Chinese authorities have granted the first invention patent to a domestically developed COVID-19 vaccine candidate, which experts said enhances the international market’s trust in Chinese-developed coronavirus vaccines and demonstrates the vaccine’s originality and creativity.
The vaccine is co-developed by Chinese biopharmaceutical firm CanSino Biologics and a team led by Chinese military infectious disease expert Chen Wei.
According to a document published on China’s National Intellectual Property Administration website, the vaccine can be mass-produced in a short time in the event of an outbreak.
The grant of the patent further confirmed the vaccine’s efficacy and safety and convincingly demonstrated the ownership of its intellectual property rights, CanSino said in a statement on Sunday.
Tao Lina, a Shanghai-based vaccine expert, said the patent grant would probably facilitate the vaccine’s marketing process.